Abeona Therapeutics Inc (NASDAQ:ABEO) shares fell 0% on Friday . The stock traded as low as $15.90 and last traded at $18.88. 3,849,722 shares changed hands during mid-day trading, an increase of 257% from the average session volume of 1,077,610 shares. The stock had previously closed at $18.88.
ABEO has been the subject of several research analyst reports. Maxim Group set a $35.00 price objective on Abeona Therapeutics and gave the stock a “buy” rating in a report on Tuesday, May 8th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Abeona Therapeutics in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Abeona Therapeutics in a report on Thursday, February 1st. BidaskClub raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, ValuEngine raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. Abeona Therapeutics has an average rating of “Buy” and a consensus target price of $28.50.
Get Abeona Therapeutics alerts:
The firm has a market capitalization of $993.41 million, a P/E ratio of -28.60 and a beta of 1.27.
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Monday, May 14th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. Abeona Therapeutics had a negative return on equity of 23.57% and a negative net margin of 939.83%. The company had revenue of $2.60 million during the quarter, compared to analyst estimates of $0.27 million. research analysts anticipate that Abeona Therapeutics Inc will post -0.76 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in ABEO. Viking Global Investors LP grew its holdings in Abeona Therapeutics by 80.5% during the fourth quarter. Viking Global Investors LP now owns 4,040,727 shares of the biopharmaceutical company’s stock valued at $64,046,000 after purchasing an additional 1,802,007 shares during the period. Millennium Management LLC grew its holdings in Abeona Therapeutics by 2,357.3% during the first quarter. Millennium Management LLC now owns 916,256 shares of the biopharmaceutical company’s stock valued at $13,148,000 after purchasing an additional 878,969 shares during the period. Nexthera Capital LP bought a new stake in Abeona Therapeutics during the first quarter valued at about $5,302,000. BlackRock Inc. grew its holdings in Abeona Therapeutics by 15.1% during the fourth quarter. BlackRock Inc. now owns 1,868,378 shares of the biopharmaceutical company’s stock valued at $29,614,000 after purchasing an additional 245,217 shares during the period. Finally, Sphera Funds Management LTD. bought a new stake in Abeona Therapeutics during the fourth quarter valued at about $3,329,000. 62.04% of the stock is owned by institutional investors and hedge funds.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.